Skip to main content
Top
Published in: Journal of Clinical Immunology 3/2007

01-05-2007 | Original Paper

CD4 +CD25 + Regulatory T Cells Decreased the Antitumor Activity of Cytokine-Induced Killer (CIK) Cells of Lung Cancer Patients

Authors: Hui Li, Jin-Pu Yu, Shui Cao, Feng Wei, Peng Zhang, Xiu-Mei An, Zong-Tang Huang, Xiu-Bao Ren

Published in: Journal of Clinical Immunology | Issue 3/2007

Login to get access

 

CD4 +CD25 + regulatory T cells (Tregs) have been shown to inhibit cytotoxic lymphocytes-mediated immune responses. Cytokine-induced killer (CIK) cells exert high impact on adoptive immunotherapeutic approaches. Therefore, the purpose of this report was to determine the effect of Tregs on CIK cell growth and CIK-induced cytotoxicity for inhibition of tumor growth in vivo as well as in vitro. After depletion of CD4 +CD25 + cells before culture, the proliferation and cytotoxicity of CIK cells, which indicated in bromodeoxyuridine (BrdU) and lactic dehydrogenase (LDH) assays, were significantly increased. Depletion of CD4 +CD25 + cells preculture also enhanced the suppression effect on the lung cancer cells inoculated in experimental animals. Blockage of glucocorticoid-induced tumor necrosis factor receptor (GITR) and transforming growth factor β1 (TGF-β1) by antibodies partially abrogated the suppressive effect of CD4 +CD25 + cells on CIK. These results indicated that Tregs could inhibit the antitumor activity of CIK cells. The molecules TGF-β and GITR may contribute to the suppressive function of CD4 +CD25 + cells.
Literature
1.
go back to reference Sakaguchi S: Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531–562, 2004PubMedCrossRef Sakaguchi S: Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531–562, 2004PubMedCrossRef
2.
go back to reference Antony PA, Piccirillo CA, Akpinarli A, et al.: CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174:2591–2601, 2005PubMed Antony PA, Piccirillo CA, Akpinarli A, et al.: CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174:2591–2601, 2005PubMed
3.
go back to reference Smyth MJ, Teng MW, Swann J, et al.: CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 176:1582–1587, 2006PubMed Smyth MJ, Teng MW, Swann J, et al.: CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 176:1582–1587, 2006PubMed
4.
go back to reference Azuma T, Takahashi T, Kunisato A, et al.: Human CD4+CD25+ regulatory T cells suppress NKT cell functions. Cancer Res 63:4516–4520, 2003PubMed Azuma T, Takahashi T, Kunisato A, et al.: Human CD4+CD25+ regulatory T cells suppress NKT cell functions. Cancer Res 63:4516–4520, 2003PubMed
5.
go back to reference Knutson KL, Dang Y, Lu H, et al.: IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol 177:84–91, 2006PubMed Knutson KL, Dang Y, Lu H, et al.: IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol 177:84–91, 2006PubMed
6.
go back to reference Taieb J, Chaput N, Schartz N, et al.: Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol 176:2722–2729, 2006PubMed Taieb J, Chaput N, Schartz N, et al.: Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol 176:2722–2729, 2006PubMed
7.
go back to reference Leemhuis T, Wells S, Scheffold C, et al.: A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 11:181–187, 2005PubMedCrossRef Leemhuis T, Wells S, Scheffold C, et al.: A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 11:181–187, 2005PubMedCrossRef
8.
go back to reference Zhang YS, Yuan FJ, Jia GF, et al.: CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R. World J Gastroenterol 11:3339–45, 2005PubMed Zhang YS, Yuan FJ, Jia GF, et al.: CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R. World J Gastroenterol 11:3339–45, 2005PubMed
9.
go back to reference Ren X, Yu J, Liu H, et al.: Th1 bias in PBMC induced by multicycles of auto-CIKs infusion in malignant solid tumor patients. Cancer Biotherapy & Radiopharmaceuticals 2006; 21(1):22–33 Ren X, Yu J, Liu H, et al.: Th1 bias in PBMC induced by multicycles of auto-CIKs infusion in malignant solid tumor patients. Cancer Biotherapy & Radiopharmaceuticals 2006; 21(1):22–33
10.
go back to reference Schmidt-Wolf IGH, Lefterova P, Mehta BA, et al.: Phenotypic characterization and identification effector cells involved in tumor cells recognition of cytokine-induced killer cells. Exp Haematol 21:1673–1679, 1993 Schmidt-Wolf IGH, Lefterova P, Mehta BA, et al.: Phenotypic characterization and identification effector cells involved in tumor cells recognition of cytokine-induced killer cells. Exp Haematol 21:1673–1679, 1993
11.
go back to reference Khazaie K, von Boehmer H: The impact of CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer. Semin Cancer Biol 16:124–136, 2006PubMedCrossRef Khazaie K, von Boehmer H: The impact of CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer. Semin Cancer Biol 16:124–136, 2006PubMedCrossRef
12.
go back to reference Comes A, Rosso O, Orengo AM, et al.: CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J Immunol 176:1750–1758, 2006PubMed Comes A, Rosso O, Orengo AM, et al.: CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J Immunol 176:1750–1758, 2006PubMed
13.
go back to reference Chakraborty NG, Chattopadhyay S, Mehrotra S, et al.: Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. Hum Immunol 65:794–802, 2004PubMedCrossRef Chakraborty NG, Chattopadhyay S, Mehrotra S, et al.: Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. Hum Immunol 65:794–802, 2004PubMedCrossRef
14.
go back to reference Kanamaru F, Youngnak P, Hashiguchi M, et al.: Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells. J Immunol 172:7306–7314, 2004PubMed Kanamaru F, Youngnak P, Hashiguchi M, et al.: Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells. J Immunol 172:7306–7314, 2004PubMed
15.
go back to reference Chen WJ, Wahl SM: TGF-b: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev 14:85–89, 2003PubMedCrossRef Chen WJ, Wahl SM: TGF-b: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev 14:85–89, 2003PubMedCrossRef
16.
go back to reference Marie JC, Letterio JJ, Gavin M, et al.: TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 201(7):1061–1067, 2005PubMedCrossRef Marie JC, Letterio JJ, Gavin M, et al.: TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 201(7):1061–1067, 2005PubMedCrossRef
17.
go back to reference Birebent B, Lorho R, Lechartier H, et al.: Suppressive properties of human CD4+CD25+ regulatory T cells are dependent on CTLA-4 expression. Eur J Immunol 34:3485–3496, 2004PubMedCrossRef Birebent B, Lorho R, Lechartier H, et al.: Suppressive properties of human CD4+CD25+ regulatory T cells are dependent on CTLA-4 expression. Eur J Immunol 34:3485–3496, 2004PubMedCrossRef
Metadata
Title
CD4 +CD25 + Regulatory T Cells Decreased the Antitumor Activity of Cytokine-Induced Killer (CIK) Cells of Lung Cancer Patients
Authors
Hui Li
Jin-Pu Yu
Shui Cao
Feng Wei
Peng Zhang
Xiu-Mei An
Zong-Tang Huang
Xiu-Bao Ren
Publication date
01-05-2007
Published in
Journal of Clinical Immunology / Issue 3/2007
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-007-9076-0

Other articles of this Issue 3/2007

Journal of Clinical Immunology 3/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.